Loading…
Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial
OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design...
Saved in:
Published in: | The American journal of psychiatry 2006-03, Vol.163 (3), p.494-499 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3 |
---|---|
cites | cdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3 |
container_end_page | 499 |
container_issue | 3 |
container_start_page | 494 |
container_title | The American journal of psychiatry |
container_volume | 163 |
creator | Gopalakrishnan, Rajesh Jacob, K.S. Kuruvilla, Anju Vasantharaj, B. John, Jacob K. |
description | OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated. |
doi_str_mv | 10.1176/appi.ajp.163.3.494 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19727888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1005829321</sourcerecordid><originalsourceid>FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhiMEoqXwAhyQhQSnZms7ceJwW3ZbqFQJBIvgZjn2WPXKawc7AZa34U1x2BWVOHCyR_pm5h99RfGU4AUhbXMhh8Eu5HZYkKZaVIu6q-8Vp4RVrGwp5feLU4wxLTtWfTkpHqW0zSWuWvqwOCENIxVv6Wnx66N1Grw01iHr0XgLaBNBjjvwIwoGLf1oh7RXt2G0qrz2elKg0WUENVoHaL1PZvL5H_wrtEQfpNdhZ3-CPkfrMPUOytfO-ly9d1JBH8pV8GMMzs3ElYMfdmbWIcE52nwP5We5R6sYUgrfIOYkVrrHxQMjXYInx_es-HR1uVm9LW_evbleLW9KWXdsLBsNBLeqIjXm0DSyNqqtDaeGd4wRzSlTqqt7pXXPZMcV7luNG8U5M9JUWFZnxcvD3CGGrxOkUexsUuCc9BCmJEjX0pZznsHn_4DbMEWfswlKMcMNrmeIHiA1XxPBiCHanYx7QbCY7YnZnsj2RLYnKpHt5aZnx8lTvwN913LUlYEXR0AmJZ2J0iub7riWccLoPOjiwP1Z8jfef1b_Bv1UtgM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220506048</pqid></control><display><type>article</type><title>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</title><source>American Psychiatric Publishing Journals (1997-Present)</source><creator>Gopalakrishnan, Rajesh ; Jacob, K.S. ; Kuruvilla, Anju ; Vasantharaj, B. ; John, Jacob K.</creator><creatorcontrib>Gopalakrishnan, Rajesh ; Jacob, K.S. ; Kuruvilla, Anju ; Vasantharaj, B. ; John, Jacob K.</creatorcontrib><description>OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.163.3.494</identifier><identifier>PMID: 16513872</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use ; Adult ; Antipsychotic Agents - adverse effects ; Biological and medical sciences ; Clinical trials ; Comorbidity ; Cross-Over Studies ; Diabetes ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Erectile Dysfunction - chemically induced ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - epidemiology ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Patients ; Pharmacology. Drug treatments ; Physical examinations ; Piperazines - therapeutic use ; Placebos ; Prolactin - blood ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Purines ; Regression Analysis ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - epidemiology ; Schizophrenia, Paranoid - drug therapy ; Schizophrenia, Paranoid - epidemiology ; Schizophrenia, Paranoid - psychology ; Sexual behavior ; Sexual Behavior - psychology ; Sexual disorders ; Sildenafil Citrate ; Sulfones ; Treatment Outcome</subject><ispartof>The American journal of psychiatry, 2006-03, Vol.163 (3), p.494-499</ispartof><rights>2006 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Mar 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</citedby><cites>FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.163.3.494$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.3.494$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2841,21606,21607,21608,27903,27904,77541,77546</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17581524$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16513872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gopalakrishnan, Rajesh</creatorcontrib><creatorcontrib>Jacob, K.S.</creatorcontrib><creatorcontrib>Kuruvilla, Anju</creatorcontrib><creatorcontrib>Vasantharaj, B.</creatorcontrib><creatorcontrib>John, Jacob K.</creatorcontrib><title>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated.</description><subject>3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use</subject><subject>Adult</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Comorbidity</subject><subject>Cross-Over Studies</subject><subject>Diabetes</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Erectile Dysfunction - chemically induced</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - epidemiology</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Physical examinations</subject><subject>Piperazines - therapeutic use</subject><subject>Placebos</subject><subject>Prolactin - blood</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Purines</subject><subject>Regression Analysis</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - epidemiology</subject><subject>Schizophrenia, Paranoid - drug therapy</subject><subject>Schizophrenia, Paranoid - epidemiology</subject><subject>Schizophrenia, Paranoid - psychology</subject><subject>Sexual behavior</subject><subject>Sexual Behavior - psychology</subject><subject>Sexual disorders</subject><subject>Sildenafil Citrate</subject><subject>Sulfones</subject><subject>Treatment Outcome</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhiMEoqXwAhyQhQSnZms7ceJwW3ZbqFQJBIvgZjn2WPXKawc7AZa34U1x2BWVOHCyR_pm5h99RfGU4AUhbXMhh8Eu5HZYkKZaVIu6q-8Vp4RVrGwp5feLU4wxLTtWfTkpHqW0zSWuWvqwOCENIxVv6Wnx66N1Grw01iHr0XgLaBNBjjvwIwoGLf1oh7RXt2G0qrz2elKg0WUENVoHaL1PZvL5H_wrtEQfpNdhZ3-CPkfrMPUOytfO-ly9d1JBH8pV8GMMzs3ElYMfdmbWIcE52nwP5We5R6sYUgrfIOYkVrrHxQMjXYInx_es-HR1uVm9LW_evbleLW9KWXdsLBsNBLeqIjXm0DSyNqqtDaeGd4wRzSlTqqt7pXXPZMcV7luNG8U5M9JUWFZnxcvD3CGGrxOkUexsUuCc9BCmJEjX0pZznsHn_4DbMEWfswlKMcMNrmeIHiA1XxPBiCHanYx7QbCY7YnZnsj2RLYnKpHt5aZnx8lTvwN913LUlYEXR0AmJZ2J0iub7riWccLoPOjiwP1Z8jfef1b_Bv1UtgM</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Gopalakrishnan, Rajesh</creator><creator>Jacob, K.S.</creator><creator>Kuruvilla, Anju</creator><creator>Vasantharaj, B.</creator><creator>John, Jacob K.</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T2</scope><scope>7TK</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20060301</creationdate><title>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</title><author>Gopalakrishnan, Rajesh ; Jacob, K.S. ; Kuruvilla, Anju ; Vasantharaj, B. ; John, Jacob K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use</topic><topic>Adult</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Comorbidity</topic><topic>Cross-Over Studies</topic><topic>Diabetes</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Erectile Dysfunction - chemically induced</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - epidemiology</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Physical examinations</topic><topic>Piperazines - therapeutic use</topic><topic>Placebos</topic><topic>Prolactin - blood</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Purines</topic><topic>Regression Analysis</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - epidemiology</topic><topic>Schizophrenia, Paranoid - drug therapy</topic><topic>Schizophrenia, Paranoid - epidemiology</topic><topic>Schizophrenia, Paranoid - psychology</topic><topic>Sexual behavior</topic><topic>Sexual Behavior - psychology</topic><topic>Sexual disorders</topic><topic>Sildenafil Citrate</topic><topic>Sulfones</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gopalakrishnan, Rajesh</creatorcontrib><creatorcontrib>Jacob, K.S.</creatorcontrib><creatorcontrib>Kuruvilla, Anju</creatorcontrib><creatorcontrib>Vasantharaj, B.</creatorcontrib><creatorcontrib>John, Jacob K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gopalakrishnan, Rajesh</au><au>Jacob, K.S.</au><au>Kuruvilla, Anju</au><au>Vasantharaj, B.</au><au>John, Jacob K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>163</volume><issue>3</issue><spage>494</spage><epage>499</epage><pages>494-499</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>OBJECTIVE: Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. METHOD: The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. RESULTS: Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment for period and week effects and treatment-period interaction with Poisson regression analysis. There were no major side effects or adverse drug interactions. CONCLUSIONS: Sildenafil citrate is safe and effective in the treatment of antipsychotic-induced erectile dysfunction. It is also well tolerated.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>16513872</pmid><doi>10.1176/appi.ajp.163.3.494</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-953X |
ispartof | The American journal of psychiatry, 2006-03, Vol.163 (3), p.494-499 |
issn | 0002-953X 1535-7228 |
language | eng |
recordid | cdi_proquest_miscellaneous_19727888 |
source | American Psychiatric Publishing Journals (1997-Present) |
subjects | 3',5'-Cyclic-GMP Phosphodiesterases - therapeutic use Adult Antipsychotic Agents - adverse effects Biological and medical sciences Clinical trials Comorbidity Cross-Over Studies Diabetes Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug therapy Erectile Dysfunction - chemically induced Erectile Dysfunction - drug therapy Erectile Dysfunction - epidemiology Follow-Up Studies Humans Male Medical sciences Middle Aged Neuropharmacology Patients Pharmacology. Drug treatments Physical examinations Piperazines - therapeutic use Placebos Prolactin - blood Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Purines Regression Analysis Schizophrenia Schizophrenia - drug therapy Schizophrenia - epidemiology Schizophrenia, Paranoid - drug therapy Schizophrenia, Paranoid - epidemiology Schizophrenia, Paranoid - psychology Sexual behavior Sexual Behavior - psychology Sexual disorders Sildenafil Citrate Sulfones Treatment Outcome |
title | Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A32%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sildenafil%20in%20the%20Treatment%20of%20Antipsychotic-Induced%20Erectile%20Dysfunction:%20A%20Randomized,%20Double-Blind,%20Placebo-Controlled,%20Flexible-Dose,%20Two-Way%20Crossover%20Trial&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Gopalakrishnan,%20Rajesh&rft.date=2006-03-01&rft.volume=163&rft.issue=3&rft.spage=494&rft.epage=499&rft.pages=494-499&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.163.3.494&rft_dat=%3Cproquest_cross%3E1005829321%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a495t-6de107c31408e66a4fc74f82f89551d825cc94bcddb5a98c0b7d06c885faf30a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=220506048&rft_id=info:pmid/16513872&rfr_iscdi=true |